DOCSLIB.ORG

Non Commercial Use Only

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Non Commercial Use Only Veterinary Science Development 2017; volume 7:6245 Effects of licofelone, matory mediators in inflammation, injury, and pain settings.1 Although COX-2 specific drugs Correspondence: Correspondence: Aidin Shojaee a novel 5-LOX inhibitor, such as COXIBs (celecoxib, deracoxib, rofacox- Tabrizi, Department of Clinical Sciences, Faculty in comparison to celecoxib ib) have less gastric side effects than non- of Veterinary Medicine, Shiraz University, Shiraz, on gastric mucosa of dogs selective ones. Reports show that they are not Iran. as safe as they are expected to be.2 Tel.: +98.9171046274. Fax: +98.7132284950. E-mail: [email protected] Aidin Shojaee Tabrizi,1 Arachidonic acid (AA) is a substance that is converted to PGs and leulotriens (LTs) by COX Mohammad Azizzadeh,2 Aidin Esfandiari1 Key words: Licofelone; celecoxib; gastric lesions; and 5-lipoxygenase (LOX) enzymes, respec- dog. 1Faculty of Veterinary Medicine, Shiraz tively. LTs are responsible for inflammations University, Shiraz; 2Faculty of Veterinary and NSAIDs-induced gastrointestinal dam- Acknowledgments: the authors wish to thank the medicine, Ferdowsi University of ages. Studies showed that diminishing Research Council of the Veterinary Medicine Mashhad, Mashhad Iran leukotriene B4 levels in gastric mucosa will School of Shiraz University for their Financial result in gastroprotection against NSAIDs- Support. induced gastropathy.3 The inhibition of COX Abstract enzyme may lead to a shunt of AA metabolism Contributions: MA, AE, substantial contributions towards 5-LOX pathway, and therefore, treat- to conception and design, acquisition of data; ment with NSAIDs increase the formation of AST, substantial contributions to conception and Despite the extensive application of non- LTs possibly leading to gastric damage.4 Thus, design, acquisition of data, drafting the article or steroidal anti-inflammatory drugs (NSAIDs), revising it critically for important intellectual the idea of dual inhibition i.e. COX/5-LOX inhi- the use of these drugs is limited due to their content. bition emerged as an alternative and safe ther- adverse effects especially on gastric mucosa. apy for enhanced analgesic and anti-inflam- Dual inhibitors that inhibit both cyclooxyge- Conflict of interest: the authors declare no poten- matory effect with little or no gastric mucosal nase (COX) and lipoxygenase (LOX) metabo- tial conflict of interest. damage.5 lites are considered to have less gastric toxici- Recently, a new generation of anti-inflam- Received for publication: 8 October 2015. ty in comparison to non-selective and COX-2 matory drugs, licofelone, has been introduced onlyAccepted for publication: 27 October 2015 selective inhibitors. In this study, fifteen with the ability of simultaneous inhibition of mixed breed dogs were randomly divided into prostaglandins, leukotrienes and thrombox- This work is licensed under a Creative Commons three groups: group 1 (n=5) received placebo, anes. The promising advantage of this drug is Attribution NonCommercial 4.0 License (CC BY- group 2 (n=5) licofelone, an inhibitor of COX- NC 4.0). its higher efficacy in controlling inflammation 1, COX-2, and 5-LOX (2.5 mg/kg; twice daily) use and lower gastric adverse effects. For this rea- and group 3 (n=5) celecoxib, a COX-2 selective ©Copyright A.. Tabrizi et al., 2017 son, the present study was carried out to deter- inhibitor (3 mg/kg; twice daily) per os for 14 Licensee PAGEPress srl, Italy mine if celecoxib can be replaced by this new Veterinary Science Development 2017; 7:6245 days. All dogs underwent blinded gastroscopies drug in canine medicine. doi:10.4081/vsd.2017.6245 on days 0, 7, 14 and one week after cessation of treatment and gastric lesions were scored. Examinations to detect fecal occult blood were performed daily. Results showed that Materials and Methods licofelone is significantly better tolerated than Endoscopy procedure celecoxib in terms of gastric side effects All dogs underwent 12 hours of fasting and (P=0.008). Therefore, it seems that licofelone Animals were premedicated with intramuscular injec- can be an appropriate alternative in dogs when commercialThis study was approved by the Iranian lab- tions of Acepromazine maleate (Castran, NSAID therapy is necessary. Occult blood was oratory animal ethics framework under the Interchemie, Holland) (0.05 mg/kg) and not detected in any dog during the study. supervision of the Iranian Society for the xylazine hydrochloride (Alfasan, Woerden, Prevention of Cruelty to Animals. A total of 15 Holland) (0.5 mg/kg). They were then anes- mixed-breed dogs (mean age 1.5 years) were thetized with a combination of diazepam Non selected from different locations of Shiraz, (Phoenix Pharma Ltd., Gloucester, England) Introduction Iran. The animals were observed for seven (0.25 mg/dog), and ketamine hydrochloride days, during which their health status was (Alfasan, Woerden, Holland) (5-10 mg/kg). Non-opioid analgesics, especially non- confirmed by clinical and laboratory examina- Gastroscopy was then performed with a 7.9 steroidal anti-inflammatory drugs (NSAIDs), tions. All dogs were fed with chicken skeleton mm diameter gastroduodenoscope are one of the most frequent medications used during the study. (MEDIT/Canada) on days 0, 7, 14 and 21 to in small animal medicine. Most NSAIDs exert obtain a thorough examination of gastric their anti-inflammatory, analgesic and anti- Drug administration mucosa. The examiner (Shojaee Tabrizi) was pyretic effects by reducing the synthesis of All 15 dogs were randomly divided into three blinded to the nature of treatment. After each prostaglandins (PGs) via cyclooxygenase groups: group 1 (n=5) received encapsulated endoscopy, all equipment and instruments (COX) inhibition. COX has two distinct mem- methylcellulose (placebo) twice daily, group 2 were cleaned thoroughly and sterilized in 2% brane-anchored isoenzymes, COX-1 and COX- (n=5) received encapsulated licofelone glutaraldehyde (Behsadex, Behsa 2. The former is constitutively expressed and (Merckle GmbH, Ulm, Germany) 2.5 mg/kg Pharmaceutical, Arak, Iran) for at least 20 min, found in normal body tissues, while the latter twice daily and group 3 (n=5) celecoxib and rinsed completely with normal saline. All is expressed in most of the normal tissues at (Celexib, Darou Pakhsh, Iran) 3 mg/kg, twice observations were recorded on tape for scoring low levels and is highly induced by pro-inflam- daily per os for 14 days. the lesions. All regions of the stomach were [Veterinary Science Development 2016; 6:6245] [page 69] Article evaluated and assigned scores from 0 to 7 for their lesions, which was reflected by a lower in dogs6 and it seems that licofelone is better each endoscopic evaluation as presented in sum in their gastric lesion scores. One of them tolerated than COXIB class of NSAIDs. Also, Table 1.6 had steady score over the treatment period. results propose that leukotriene suppression One week after cessation of treatment (day via licofelone has more effective protection on Statistical analysis 21), results show that score of gastric lesions gastric mucosa than prostaglandin inhibition A non-parametric Kruskal-Wallis test at was not significantly different between groups occurring through selective or non-selective P<0.05 was used to investigate whether the at P<0.017. Indeed, gastric lesions of celecox- COX-2 actions, the fact that was previously score of gastric lesions of three groups differed ib-group and licofelone-group improved after mentioned in the study conducted by Moreau or not. The differences in gastric lesions one week of discontinuing of treatment. and colleagues. between two groups were investigated by the No abnormalities in physical or fecal exam- Using selective or non-selective COX-2 Mann-Whitney U-test. Since this was multiple inations, including fecal occult blood, were inhibitors apparently cause an imbalance that testing of the data the significance level was detected during the course of the study. shift the pathways to 5-LOX, consequently adjusted by using the Bonferroni test. Three diverting arachdonic acid to overproduction of groups were compared and therefore the sig- the noxious and chemo attractant nificance level became 0.05 divided by 3; leukotrienes.6,8-10 These events may justify the (P=0.017). Discussion and Conclusions reason why a 5-LOX inhibitor like licofelone is much better tolerated than selective and non- The aim of this study was assessing the side selective COX-2 inhibitors. effects of one of the COXIB class of NSAIDs, Since in the present study no dog had abnor- Results celecoxib, in small animal practice and com- mal clinical signs or positive result of fecal parison of it with one of the new generation of occult blood examination, our findings are in On the beginning of the study (day 0), mild this class of drug. In present study, some of the line with the results of other studies6,11 about gastric lesions were observed in two celecoxib- dogs had pre-existing lesions on day 0, before the fact that dogs with gastric lesions may not treated dogs and in four licofelone-treated starting the study, which is a common finding show any clinical or laboratory sign of gastric dogs. No lesions were observed in the placebo in dogs because of non-pylori Helicobacter damage caused by NSAIDs. Therefore, clini- group at either the baseline or the final (day infections, stress and foreign body ingestion. cian should be alert that the risk of severe 21) endoscopy. Table 2 shows the median and We did not exclude them from the study complications remains, even without any clin- quartiles of the score of gastric lesions for because most of the dogs in practice have the ical sign. each group on days 0, 7, 14 and 21. same lesions.6 Our study suggests the replacement of After one week, following 7 days of continu- Licofelone was administered at a dose of 2.5 COXIBs and non-selective NSAIDs with a 5- ous treatment, there were significant differ- mg/kg twice daily based on previous studies.6,7 LOX inhibitor, licofelon because of its excellent ences between the groups in terms of their In this study, licofelone had obviously a better safety profile.
Load more

Recommended publications
  • Non-Steroidal Anti-Inflammatory Agents – Benefits and New Developments for Cancer Pain
    Carr_subbed.qxp 22/5/09 09:49 Page 18 Supportive Oncology Non-steroidal Anti-inflammatory Agents – Benefits and New Developments for Cancer Pain a report by Daniel B Carr1 and Marie Belle D Francia2 1. Saltonstall Professor of Pain Research; 2. Special Scientific Staff, Department of Anesthesiology, Tufts Medical Center DOI: 10.17925/EOH.2008.04.2.18 Pain is one of the complications of cancer that patients most fear, and This article surveys the current role of NSAIDs in the management of its multifactorial aetiology makes it one of the most challenging cancer pain and elucidates newly recognised mechanisms that may conditions to treat.1 A systematic review of epidemiological studies on provide a foundation for the next generation of NSAIDs for analgesia cancer pain published between 1982 and 2001 revealed cancer pain for cancer patients. prevalence rates of at least 14%.2 A more recent systematic review identified prevalence rates of cancer pain in as many as one-third of Mechanism of Analgesic Effects patients after curative treatment and two-thirds of patients NSAIDs are a structurally diverse group of compounds known to undergoing treatment regardless of the stage of disease. The wide prevent the formation of prostanoids (prostaglandins and variation in published prevalence rates is due to heterogeneity of the thromboxane) from arachidonic acid through the inhibition of the populations studied, diverse settings, site of primary cancer and stage enzyme cyclo-oxygenase (COX; see Table 1). COX has two isoenzymes: and methodology used to ascertain prevalence.1 COX-1 is found ubiquitously in most tissues and produces prostaglandins and thromboxane, while COX-2 is located in certain A multimodal approach to the treatment of cancer pain that deploys tissues (brain, blood vessels and so on) and its expression increases both pharmacological and non-pharmacological methods may be during inflammation or fever.
    [Show full text]
  • Pain Management in Companion Animals
    CONTINUING EDUCATION TAP OUR APP Pain Management in Companion Animals Download “NCPA Mobile” Today! by Ann Philbrick, PharmD, BCPS Don’t be left out of the latest news affecting community pharmacy—download our new app, NCPA Mobile! Receive real-time updates, join the conversation on Twitter with a built-in feed, Jul. 1, 2015 (expires Jul. 1, 2018) and never miss out on breaking news affecting community pharmacy. Keep the Activity Type: Application-based app on your phone year-round for updates, news, alerts, and more from NCPA. To earn continuing education credit: ACPE Program 0207-0000-15-007-H01-P; 0207-0000-15-007-H01-T Upon successful completion of this article, the pharmacist should be able to: 1. Describe the process of pain in the dog and cat including identification of ways they express pain. 2. Describe the appropriate use, mechanism of action, and precautions for use of analgesics in the treatment of pain in dogs and cats. 3. Explain the key issues that impair the prevention of diversion in compan- ion animal owners. Upon successful completion of this article, the pharmacist should be able to: 1. Describe the process of pain in the dog and cat including identification of ways they express pain. To get the free NCPA Mobile app: 2. Describe the appropriate use, mechanism of action, and precautions for FREE ONLINE CE. To take advantage use of analgesics in the treatment of pain in dogs and cats. of free continuing pharmacy educa- iPhone and iPad users—search “NCPA 3. Explain the key issues that impair the prevention of diversion in compan- tion (CPE) for this program, pharma- ion animal owners.
    [Show full text]
  • Licofelone-DPPC Interactions: Putting Membrane Lipids on the Radar of Drug Development
    molecules Article Licofelone-DPPC Interactions: Putting Membrane Lipids on the Radar of Drug Development Catarina Pereira-Leite 1,2 , Daniela Lopes-de-Campos 1, Philippe Fontaine 3 , Iolanda M. Cuccovia 2, Cláudia Nunes 1 and Salette Reis 1,* 1 LAQV, REQUIMTE, Departamento de Ciências Químicas, Faculdade de Farmácia, Universidade do Porto, Rua de Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal; [email protected] (C.P.-L.); [email protected] (D.L.-d.-C.); [email protected] (C.N.) 2 Departamento de Bioquímica, Instituto de Química, Universidade de São Paulo, Av. Prof. Lineu Prestes, 748, 05508-000 São Paulo, Brazil; [email protected] 3 Synchrotron SOLEIL, L’Orme des Merisiers, Saint Aubin, BP48, 91192 Gif-sur-Yvette, France; [email protected] * Correspondence: [email protected]; Tel.: +351-220-428-672 Academic Editors: Maria Emília De Sousa, Honorina Cidade and Carlos Manuel Afonso Received: 19 December 2018; Accepted: 30 January 2019; Published: 31 January 2019 Abstract: (1) Background: Membrane lipids have been disregarded in drug development throughout the years. Recently, they gained attention in drug design as targets, but they are still disregarded in the latter stages. Thus, this study aims to highlight the relevance of considering membrane lipids in the preclinical phase of drug development. (2) Methods: The interactions of a drug candidate for clinical use (licofelone) with a membrane model system made of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) were evaluated by combining Langmuir isotherms, Brewster angle microscopy (BAM), polarization-modulation infrared reflection-absorption spectroscopy (PM-IRRAS), and grazing-incidence X-ray diffraction (GIXD) measurements.
    [Show full text]
  • Download Product Insert (PDF)
    PRODUCT INFORMATION Deracoxib Item No. 27371 CAS Registry No.: 169590-41-4 O H2N Formal Name: 4-[3-(difluoromethyl)-5-(3-fluoro- S O 4-methoxyphenyl)-1H-pyrazol-1- yl]-benzenesulfonamide F Synonym: SC-59046 O MF: C17H14F3N3O3S 397.4 FW: N Purity: ≥98% N UV/Vis.: λmax: 256 nm Supplied as: A solid Storage: -20°C F Stability: ≥2 years F Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures Deracoxib is supplied as a solid. A stock solution may be made by dissolving the deracoxib in the solvent of choice, which should be purged with an inert gas. Deracoxib is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of deracoxib in ethanol is approximately 3 mg/ml and approximately 10 mg/ml in DMSO and DMF. Deracoxib is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, deracoxib should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Deracoxib has a solubility of approximately 0.1 mg/ml in a 1:8 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day. Description Deracoxib is a non-steroidal anti-inflammatory drug (NSAID) and selective inhibitor of COX-2 1 (IC50s = 0.63 and 23 μM for COX-2 and COX-1, respectively). In vivo, deracoxib (0.3-10 mg/kg) increases weight bearing and decreases lameness and joint effusion in a canine model of urate crystal-induced intraarticular synovitis.2 Deracoxib induces less lesion formation in the gastric mucosa of healthy canines than aspirin (Item No.
    [Show full text]
  • NSAIDS Use of Otcs Last Updated 07/10
    Adopted: 6/98 Revised: 2/05, 7/10 NSAIDs—Use of Over-the-Counter Nonsteroidal Anti-Inflammatory Drugs and Analgesics Over-the-counter (OTC) nonsteroidal anti-inflammatory drugs (NSAIDs) are used to control pain and inflammation in a variety of musculoskeletal conditions, including arthritis, low back pain and sports injuries. The main objective of this protocol is to review NSAIDs that are commonly used in clinical management of musculoskeletal conditions. Dosage, side effects, contraindications, and interactions with other medications are presented, as well as a strategy for decision-making. Although not an NSAID, the analgesic acetaminophen is also discussed. Because treatment with NSAIDs may mask or confuse the benefit of other therapies, it may be prudent to delay use of NSAIDs in some cases until the effectiveness of alternative therapy is determined. BACKGROUND Reducing Pain and Inflammation Limitations of Evidence Nonsteroidal anti-inflammatory drugs (NSAIDs) are Scientific evidence from drug trials may not commonly employed in the pharmacological apply to everyone taking a particular drug. For management of pain and inflammation. These example, minority groups, children, the drugs work by inhibiting enzymes called elderly, and persons at increased risk of cyclooxygenase 1 and 2 (COX 1-2). The COX 1-2 adverse events are often deliberately excluded enzymes are responsible for the production of from trials. Furthermore, therapeutic benefits prostaglandins, hormone-like substances involved of drugs and adverse reactions are not in inflammation and pain (Prisk 2003). NSAIDs have measured using comparable scales. Finally, been routinely used for the initial onset, drugs tend to be used for a wider range of continued relief, and re-injury or exacerbations of indications than those for which they are musculoskeletal pain.
    [Show full text]
  • Targeting Lipid Peroxidation for Cancer Treatment
    molecules Review Targeting Lipid Peroxidation for Cancer Treatment Sofia M. Clemente 1, Oscar H. Martínez-Costa 2,3 , Maria Monsalve 3 and Alejandro K. Samhan-Arias 2,3,* 1 Departamento de Química, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, 2829-516 Caparica, Portugal; [email protected] 2 Departamento de Bioquímica, Facultad de Medicina, Universidad Autónoma de Madrid (UAM), c/Arturo Duperier 4, 28029 Madrid, Spain; [email protected] 3 Instituto de Investigaciones Biomédicas ‘Alberto Sols’ (CSIC-UAM), c/Arturo Duperier 4, 28029 Madrid, Spain; [email protected] * Correspondence: [email protected] Academic Editor: Mauro Maccarrone Received: 29 September 2020; Accepted: 3 November 2020; Published: 5 November 2020 Abstract: Cancer is one of the highest prevalent diseases in humans. The chances of surviving cancer and its prognosis are very dependent on the affected tissue, body location, and stage at which the disease is diagnosed. Researchers and pharmaceutical companies worldwide are pursuing many attempts to look for compounds to treat this malignancy. Most of the current strategies to fight cancer implicate the use of compounds acting on DNA damage checkpoints, non-receptor tyrosine kinases activities, regulators of the hedgehog signaling pathways, and metabolic adaptations placed in cancer. In the last decade, the finding of a lipid peroxidation increase linked to 15-lipoxygenases isoform 1 (15-LOX-1) activity stimulation has been found in specific successful treatments against cancer. This discovery contrasts with the production of other lipid oxidation signatures generated by stimulation of other lipoxygenases such as 5-LOX and 12-LOX, and cyclooxygenase (COX-2) activities, which have been suggested as cancer biomarkers and which inhibitors present anti-tumoral and antiproliferative activities.
    [Show full text]
  • Drug and Medication Classification Schedule
    KENTUCKY HORSE RACING COMMISSION UNIFORM DRUG, MEDICATION, AND SUBSTANCE CLASSIFICATION SCHEDULE KHRC 8-020-1 (11/2018) Class A drugs, medications, and substances are those (1) that have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration. Acecarbromal Bolasterone Cimaterol Divalproex Fluanisone Acetophenazine Boldione Citalopram Dixyrazine Fludiazepam Adinazolam Brimondine Cllibucaine Donepezil Flunitrazepam Alcuronium Bromazepam Clobazam Dopamine Fluopromazine Alfentanil Bromfenac Clocapramine Doxacurium Fluoresone Almotriptan Bromisovalum Clomethiazole Doxapram Fluoxetine Alphaprodine Bromocriptine Clomipramine Doxazosin Flupenthixol Alpidem Bromperidol Clonazepam Doxefazepam Flupirtine Alprazolam Brotizolam Clorazepate Doxepin Flurazepam Alprenolol Bufexamac Clormecaine Droperidol Fluspirilene Althesin Bupivacaine Clostebol Duloxetine Flutoprazepam Aminorex Buprenorphine Clothiapine Eletriptan Fluvoxamine Amisulpride Buspirone Clotiazepam Enalapril Formebolone Amitriptyline Bupropion Cloxazolam Enciprazine Fosinopril Amobarbital Butabartital Clozapine Endorphins Furzabol Amoxapine Butacaine Cobratoxin Enkephalins Galantamine Amperozide Butalbital Cocaine Ephedrine Gallamine Amphetamine Butanilicaine Codeine
    [Show full text]
  • Chemoprevention of Urothelial Cell Carcinoma Growth and Invasion by the Dual COX–LOX Inhibitor Licofelone in UPII-SV40T Transgenic Mice
    Published OnlineFirst May 2, 2014; DOI: 10.1158/1940-6207.CAPR-14-0087 Cancer Prevention Research Article Research Chemoprevention of Urothelial Cell Carcinoma Growth and Invasion by the Dual COX–LOX Inhibitor Licofelone in UPII-SV40T Transgenic Mice Venkateshwar Madka1, Altaf Mohammed1, Qian Li1, Yuting Zhang1, Jagan M.R. Patlolla1, Laura Biddick1, Stan Lightfoot1, Xue-Ru Wu2, Vernon Steele3, Levy Kopelovich3, and Chinthalapally V. Rao1 Abstract Epidemiologic and clinical data suggest that use of anti-inflammatory agents is associated with reduced risk for bladder cancer. We determined the chemopreventive efficacy of licofelone, a dual COX–lipox- ygenase (LOX) inhibitor, in a transgenic UPII-SV40T mouse model of urothelial transitional cell carcinoma (TCC). After genotyping, six-week-old UPII-SV40T mice (n ¼ 30/group) were fed control (AIN-76A) or experimental diets containing 150 or 300 ppm licofelone for 34 weeks. At 40 weeks of age, all mice were euthanized, and urinary bladders were collected to determine urothelial tumor weights and to evaluate histopathology. Results showed that bladders of the transgenic mice fed control diet weighed 3 to 5-fold more than did those of the wild-type mice due to urothelial tumor growth. However, treatment of transgenic mice with licofelone led to a significant, dose-dependent inhibition of the urothelial tumor growth (by 68.6%–80.2%, P < 0.0001 in males; by 36.9%–55.3%, P < 0.0001 in females) compared with the control group. The licofelone diet led to the development of significantly fewer invasive tumors in these transgenic mice. Urothelial tumor progression to invasive TCC was inhibited in both male (up to 50%; P < 0.01) and female mice (41%–44%; P < 0.003).
    [Show full text]
  • JPET #139444 1 Licofelone Suppresses Prostaglandin E2
    JPET Fast Forward. Published on June 11, 2008 as DOI: 10.1124/jpet.108.139444 JPET ThisFast article Forward. has not been Published copyedited andon formatted.June 11, The 2008 final versionas DOI:10.1124/jpet.108.139444 may differ from this version. JPET #139444 Licofelone suppresses prostaglandin E2 formation by interference with the inducible microsomal prostaglandin E2 synthase-1* Andreas Koeberle, Ulf Siemoneit, Ulrike Bühring, Hinnak Northoff, Stefan Laufer, Wolfgang Albrecht and Oliver Werz Pharmaceutical Institute, University of Tuebingen, Auf der Morgenstelle 8, D-72076 Downloaded from Tuebingen, Germany (A.K., U.S., U.B., S.L., W.A., O.W.) Institute for Clinical and Experimental Transfusion Medicine, University Medical Center jpet.aspetjournals.org Tuebingen, Hoppe-Seyler-Straße 3, 72076 Tuebingen, Germany (H.N.) at ASPET Journals on September 27, 2021 1 Copyright 2008 by the American Society for Pharmacology and Experimental Therapeutics. JPET Fast Forward. Published on June 11, 2008 as DOI: 10.1124/jpet.108.139444 This article has not been copyedited and formatted. The final version may differ from this version. JPET #139444 Running title: Licofelone inhibits mPGES-1 Correspondence to: Dr. Oliver Werz, Department of Pharmaceutical Analytics, Pharmaceutical Institute, University of Tuebingen, Auf der Morgenstelle 8, D-72076 Tuebingen, Germany. Phone: +4970712972470; Fax: +497071294565; e-mail: [email protected] Downloaded from Number of text pages: 31 Tables: 0 Figures: 4 jpet.aspetjournals.org References: 40 Words
    [Show full text]
  • Dog Owner Information About ® Chewable Tablets (Carprofen)
    Dog Owner Information about ® Chewable Tablets (carprofen) ® Caplets (carprofen, USP) Rimadyl® (pronounced “Rim-a-dill”) for Osteoarthritis and Post-Surgical Pain Generic name: carprofen (“car-pro-fen”) This summary contains important information about Rimadyl. You should read this What are the possible side effects that may occur in my dog during information before you start giving your dog Rimadyl and review it each time the Rimadyl therapy? prescription is refilled. This sheet is provided only as a summary and does not take Rimadyl, like other drugs, may cause some side effects. Serious but rare side effects the place of instructions from your veterinarian. Talk to your veterinarian if you do not have been reported in dogs taking NSAIDs, including Rimadyl. Serious side effects can understand any of this information or if you want to know more about Rimadyl. occur with or without warning and in rare situations result in death. What is Rimadyl? The most common NSAID-related side effects generally involve the stomach (such as Rimadyl is a nonsteroidal anti-inflammatory drug (NSAID) that is used to reduce pain bleeding ulcers), and liver or kidney problems. Look for the following side effects that and inflammation (soreness) due to osteoarthritis and pain following surgery in dogs. can indicate your dog may be having a problem with Rimadyl or may have another Rimadyl is a prescription drug for dogs. It is available as a caplet and chewable tablet medical problem: and is given to dogs by mouth. • Decrease or increase in appetite Osteoarthritis
    [Show full text]
  • The Roles of Prostaglandin F2 in Regulating the Expression of Matrix Metalloproteinase-12 Via an Insulin Growth Factor-2-Dependent Mechanism in Sheared Chondrocytes
    Signal Transduction and Targeted Therapy www.nature.com/sigtrans ARTICLE OPEN The roles of prostaglandin F2 in regulating the expression of matrix metalloproteinase-12 via an insulin growth factor-2-dependent mechanism in sheared chondrocytes Pei-Pei Guan1, Wei-Yan Ding1 and Pu Wang 1 Osteoarthritis (OA) was recently identified as being regulated by the induction of cyclooxygenase-2 (COX-2) in response to high 12,14 fluid shear stress. Although the metabolic products of COX-2, including prostaglandin (PG)E2, 15-deoxy-Δ -PGJ2 (15d-PGJ2), and PGF2α, have been reported to be effective in regulating the occurrence and development of OA by activating matrix metalloproteinases (MMPs), the roles of PGF2α in OA are largely overlooked. Thus, we showed that high fluid shear stress induced the mRNA expression of MMP-12 via cyclic (c)AMP- and PGF2α-dependent signaling pathways. Specifically, we found that high fluid shear stress (20 dyn/cm2) significantly increased the expression of MMP-12 at 6 h ( > fivefold), which then slightly decreased until 48 h ( > threefold). In addition, shear stress enhanced the rapid synthesis of PGE2 and PGF2α, which generated synergistic effects on the expression of MMP-12 via EP2/EP3-, PGF2α receptor (FPR)-, cAMP- and insulin growth factor-2 (IGF-2)-dependent phosphatidylinositide 3-kinase (PI3-K)/protein kinase B (AKT), c-Jun N-terminal kinase (JNK)/c-Jun, and nuclear factor kappa-light- chain-enhancer of activated B cells (NF-κB)-activating pathways. Prolonged shear stress induced the synthesis of 15d-PGJ2, which is responsible for suppressing the high levels of MMP-12 at 48 h.
    [Show full text]
  • Nonsteroidal Anti-Inflammatory Drugs for Dysmenorrhoea (Review)
    Cochrane Database of Systematic Reviews Nonsteroidal anti-inflammatory drugs for dysmenorrhoea (Review) Marjoribanks J, Ayeleke RO, Farquhar C, Proctor M Marjoribanks J, Ayeleke RO, Farquhar C, Proctor M. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database of Systematic Reviews 2015, Issue 7. Art. No.: CD001751. DOI: 10.1002/14651858.CD001751.pub3. www.cochranelibrary.com Nonsteroidal anti-inflammatory drugs for dysmenorrhoea (Review) Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . ..... 4 BACKGROUND .................................... 5 OBJECTIVES ..................................... 6 METHODS ...................................... 6 Figure1. ..................................... 8 Figure2. ..................................... 10 Figure3. ..................................... 12 RESULTS....................................... 14 Figure4. ..................................... 16 Figure5. ..................................... 18 Figure6. ..................................... 24 ADDITIONALSUMMARYOFFINDINGS . 25 DISCUSSION ..................................... 26 AUTHORS’CONCLUSIONS . 27 ACKNOWLEDGEMENTS . 27 REFERENCES ..................................... 28 CHARACTERISTICSOFSTUDIES . 40 DATAANDANALYSES. 130 Analysis 1.1. Comparison 1 NSAIDs vs placebo, Outcome 1 Pain relief dichotomous data. 136
    [Show full text]